360 related articles for article (PubMed ID: 23740440)
1. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
[TBL] [Abstract][Full Text] [Related]
3. Role of non-inflammatory factors in intestinal fibrosis.
Zhao JF; Ling FM; Li JR; Chen YD; Huang L; Zhu LR
J Dig Dis; 2020 Jun; 21(6):315-318. PubMed ID: 32406603
[TBL] [Abstract][Full Text] [Related]
4. Features of intestinal lesions in the clinical course of inflammatory bowel diseases.
Vetuschi A; Latella G; Pompili S; Gaudio E; Sferra R
Ital J Anat Embryol; 2014; 119(3):286-303. PubMed ID: 26749690
[TBL] [Abstract][Full Text] [Related]
5. PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD.
Vetuschi A; Pompili S; Gaudio E; Latella G; Sferra R
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8839-8848. PubMed ID: 30575926
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
Bettenworth D; Rieder F
Dig Dis; 2017; 35(1-2):25-31. PubMed ID: 28147352
[TBL] [Abstract][Full Text] [Related]
7. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.
Latella G; Rogler G; Bamias G; Breynaert C; Florholmen J; Pellino G; Reif S; Speca S; Lawrance IC
J Crohns Colitis; 2014 Oct; 8(10):1147-65. PubMed ID: 24731838
[TBL] [Abstract][Full Text] [Related]
8. Intestinal fibrosis in IBD--a dynamic, multifactorial process.
Rieder F; Fiocchi C
Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):228-35. PubMed ID: 19347014
[TBL] [Abstract][Full Text] [Related]
9. Intestinal fibrosis: ready to be reversed.
Latella G; Rieder F
Curr Opin Gastroenterol; 2017 Jul; 33(4):239-245. PubMed ID: 28402994
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease.
Zorzi F; Calabrese E; Monteleone G
Clin Sci (Lond); 2015 Dec; 129(12):1107-13. PubMed ID: 26494636
[TBL] [Abstract][Full Text] [Related]
11. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases.
Szabò H; Fiorino G; Spinelli A; Rovida S; Repici A; Malesci AC; Danese S
Aliment Pharmacol Ther; 2010 Jan; 31(2):189-201. PubMed ID: 19832726
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of tissue remodeling in inflammatory bowel disease.
Rieder F; Fiocchi C
Dig Dis; 2013; 31(2):186-93. PubMed ID: 24030223
[TBL] [Abstract][Full Text] [Related]
13. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.
Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K
Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558
[TBL] [Abstract][Full Text] [Related]
14. Nr4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts.
Pulakazhi Venu VK; Alston L; Iftinca M; Tsai YC; Stephens M; Warriyar K V V; Rehal S; Hudson G; Szczepanski H; von der Weid PY; Altier C; Hirota SA
Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(3):G280-G297. PubMed ID: 34288735
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?
Rogler G
Dig Dis; 2014; 32 Suppl 1():39-49. PubMed ID: 25531352
[TBL] [Abstract][Full Text] [Related]
16. Significant contribution of TRPC6 channel-mediated Ca
Kurahara LH; Hiraishi K; Sumiyoshi M; Doi M; Hu Y; Aoyagi K; Jian Y; Inoue R
J Smooth Muscle Res; 2016; 52(0):78-92. PubMed ID: 27818466
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
Rieder F; Fiocchi C; Rogler G
Gastroenterology; 2017 Feb; 152(2):340-350.e6. PubMed ID: 27720839
[TBL] [Abstract][Full Text] [Related]
18. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.
Papa A; Scaldaferri F; Danese S; Guglielmo S; Roberto I; Bonizzi M; Mocci G; Felice C; Ricci C; Andrisani G; Fedeli G; Gasbarrini G; Gasbarrini A
Dig Dis; 2008; 26(2):149-55. PubMed ID: 18431065
[TBL] [Abstract][Full Text] [Related]
19. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.
Bamias G; Pizarro TT; Cominelli F
Inflamm Bowel Dis; 2022 Mar; 28(3):337-349. PubMed ID: 34904152
[TBL] [Abstract][Full Text] [Related]
20. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
